PIK3CA and neoplasm: After calibration, the model was also able to reproduce the tumor volume evolution after gefitinib or osimertinib treatment in mice transplanted with xenografts bearing an EGFR exon 19 deletion (Figure 3) and also with xenografts bearing both an EGFR exon 19 deletion and a PIK3CA mutation (Palgen et al. [35]).